|Report Code: PP10188
|Report Type: Molecule-Type Pipeline Reports
Peptides are structurally similar to protein, comprising of peptide bonds, but smaller than proteins. A peptide bond is formed when two amino acids are combined through amide formation (combination of carboxyl group of one amino acid and amino group of the other amino acid). Similarly, dipeptide is a molecule having two peptide bonds, tripeptide having three, and so on. Peptides fall between small molecules and large biologics, in terms of molecular weight. P113 by Pacgen Life Science Corporation is an antimicrobial peptide and is derived from histatin protein found in human saliva. Histatin protein has an important role in eliminating oral diseases, such as oral candidiasis and oesophagus infection.
Rhythm Pharmaceuticals Inc. is developing setmelanotide as a MC4R agonist for the treatment of rare genetic disorders of obesity. Madam Therapeutics is developing antimicrobial SAAP-148 for the treatment of wounds due to diabetic foot and pressure ulcers, burning wounds, and methicillin-resistant Staphylococcus aureus (MRSA). Almac Group is formulating ALM 201 as an angiogenesis inhibitor for the treatment of ovarian cancer and ophthalmology disorders. Some of the companies developing peptide therapeutics are Jitsubo Co. Ltd. and BrightPath Biotherapeutics Co. Ltd.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.